Market Cap 5.08B
Revenue (ttm) 3.70B
Net Income (ttm) 280.09M
EPS (ttm) N/A
PE Ratio 19.14
Forward PE 19.48
Profit Margin 7.57%
Debt to Equity Ratio 0.29
Volume 60,975
Avg Vol 375,552
Day's Range N/A - N/A
Shares Out 30.88M
Stochastic %K 66%
Beta 0.11
Analysts Sell
Price Target $166.00

Company Profile

FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through Corporate Finance & Restructuring; Forensic and Litigation Consulting; Economic Consulting; and Technology, and Strategic Communications segments. The Corporate Finance & Restructuring segment provides business transformation and strategy, transactions, and turnaround and restructuring services. The Forensic and Litigation Consulting segment offer...

Industry: Consulting Services
Sector: Industrials
Phone: 202 312 9100
Fax: 202 312 9101
Address:
555 12th Street NW, Suite 700, Washington, United States
Iightning
Iightning Dec. 4 at 5:07 AM
1ightning® Premium Options Alert (Actionable) Ticker: $FCN Contract: Dec 19 $170C Entry: 1.68 Exit: 2.77 Return: +65.39% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:55 AM
$FCN $LMDX $RHHBY $SPY Part 3 If proven, this may constitute: • fraudulent transfer (moving value out of reach of stakeholders) • breach of fiduciary duty (self-dealing, failing to maximize value) • market misrepresentation (omitting material assets and conflicts) • pre-pack phoenixing (continuing the enterprise through new entities) • insolvency abuse (undervalue transactions and director misfeasance)
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:54 AM
$FCN $LMDX $RHHBY $SPY Part 2 Shareholders received nothing because the insiders structured the process as an asset sale, not a company sale. Executives resigned at critical moments, reappeared in successor companies, and controlled the wind-down while holding shares, options, or conflicts of interest. Key pipeline assets (especially the TB test) were never independently valued, never disclosed properly, and never included in the sale consideration. This has the hallmarks of a coordinated scheme in which insiders: • declared insolvency while still holding valuable undeclared assets • transferred or shielded IP and operating capabilities • sold core assets to Roche at an undervalued price • preserved continuity in new entities they controlled • left shareholders with a hollow shell and zero recovery
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:53 AM
$LMDX $FCN $RHHBY $SPY $ELECTRADX $TAUN What my research tells me… Part 1 LumiraDx’s collapse was not a normal insolvency. The company’s valuable assets—its POC platform, TB test, SureSensors biosensor IP, Invita software/data, manufacturing know-how, and scientific talent—were quietly split, withheld, or redirected before and during the liquidation process. Roche acquired the commercial POC assets cheaply, while other high-value components resurfaced in spinouts and successor entities tied to former LMDX insiders (Invita/IVD Intelligence, ElectraDx, SureSensors continuity, LKM).
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 1:52 AM
$LMDX $FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:55 AM
$FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:52 AM
$LMDX $RHHBY $FCN $SPY $ELECTRADX $TAUN Here’s more info, imo from a shareholder perspective, the sequence of events surrounding Invita, LumiraDx, and ElectraDx raises multiple red flags consistent with potential asset diversion, insider preference, and misleading financial disclosure. Invita Technologies was formally separated from LumiraDx in September 2023—immediately prior to the company’s abrupt collapse in reported assets, including a documented loss of approximately $50 million in total and current assets within a two-month period. During the same window, LumiraDx executives publicly claimed that digital assets and software platforms remained part of the group, yet Invita—housing precisely those assets—was quietly removed from the balance sheet. Shortly thereafter, key technical, scientific, and digital-infrastructure personnel who had built LumiraDx’s proprietary systems resurfaced at ElectraDx, an entity controlled by Ron Zwanziger and other former LumiraDx insiders.
1 · Reply
Iightning
Iightning Dec. 3 at 9:19 AM
1ightning® Premium Options Alert (Actionable) Ticker: $FCN Contract: Dec 19 $150C Entry: 16.50 Exit: 21.15 Return: +28.15% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 3:20 AM
$LMDX $RHHBY $SPY $FCN $ELECTRADX $TAUNS In my opinion, the timing of the Invita separation, the sudden deterioration of LumiraDx’s balance sheet, and the rapid emergence of ElectraDx with many of the same insiders is too aligned to ignore. Taken together, these events strongly suggest that key digital assets were repositioned ahead of insolvency, creating a continuity structure that benefited insiders while shareholders were wiped out.
0 · Reply
Iightning
Iightning Dec. 1 at 11:20 PM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $FCN **Contract:** Dec 19 $165C **Entry:** 4.57 **Exit:** 7.61 **Return:** **+66.27% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Latest News on FCN
FTI Consulting (FCN) Q3 2025 Earnings Transcript

Oct 23, 2025, 1:01 PM EDT - 6 weeks ago

FTI Consulting (FCN) Q3 2025 Earnings Transcript


FTI Consulting, Inc. (FCN) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 12:47 PM EDT - 6 weeks ago

FTI Consulting, Inc. (FCN) Q3 2025 Earnings Call Transcript


FTI Consulting Announces CFO Transition

Aug 12, 2025, 7:00 AM EDT - 4 months ago

FTI Consulting Announces CFO Transition


FTI Consulting Tops Q2 Estimates

Jul 25, 2025, 7:22 PM EDT - 4 months ago

FTI Consulting Tops Q2 Estimates


FTI Consulting, Inc. (FCN) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 2:22 PM EDT - 4 months ago

FTI Consulting, Inc. (FCN) Q2 2025 Earnings Call Transcript


FTI Consulting FCN Q2 2025 Earnings Transcript

Jul 24, 2025, 10:19 AM EDT - 4 months ago

FTI Consulting FCN Q2 2025 Earnings Transcript


FTI Consulting Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:30 AM EDT - 4 months ago

FTI Consulting Reports Second Quarter 2025 Financial Results


FTI Consulting: A Hidden Gem or Just Fine?

Jun 3, 2025, 7:00 PM EDT - 6 months ago

FTI Consulting: A Hidden Gem or Just Fine?


FTI Consulting Announces Technology Alliance with BigID

May 20, 2025, 7:30 AM EDT - 7 months ago

FTI Consulting Announces Technology Alliance with BigID


Iightning
Iightning Dec. 4 at 5:07 AM
1ightning® Premium Options Alert (Actionable) Ticker: $FCN Contract: Dec 19 $170C Entry: 1.68 Exit: 2.77 Return: +65.39% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:55 AM
$FCN $LMDX $RHHBY $SPY Part 3 If proven, this may constitute: • fraudulent transfer (moving value out of reach of stakeholders) • breach of fiduciary duty (self-dealing, failing to maximize value) • market misrepresentation (omitting material assets and conflicts) • pre-pack phoenixing (continuing the enterprise through new entities) • insolvency abuse (undervalue transactions and director misfeasance)
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:54 AM
$FCN $LMDX $RHHBY $SPY Part 2 Shareholders received nothing because the insiders structured the process as an asset sale, not a company sale. Executives resigned at critical moments, reappeared in successor companies, and controlled the wind-down while holding shares, options, or conflicts of interest. Key pipeline assets (especially the TB test) were never independently valued, never disclosed properly, and never included in the sale consideration. This has the hallmarks of a coordinated scheme in which insiders: • declared insolvency while still holding valuable undeclared assets • transferred or shielded IP and operating capabilities • sold core assets to Roche at an undervalued price • preserved continuity in new entities they controlled • left shareholders with a hollow shell and zero recovery
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:53 AM
$LMDX $FCN $RHHBY $SPY $ELECTRADX $TAUN What my research tells me… Part 1 LumiraDx’s collapse was not a normal insolvency. The company’s valuable assets—its POC platform, TB test, SureSensors biosensor IP, Invita software/data, manufacturing know-how, and scientific talent—were quietly split, withheld, or redirected before and during the liquidation process. Roche acquired the commercial POC assets cheaply, while other high-value components resurfaced in spinouts and successor entities tied to former LMDX insiders (Invita/IVD Intelligence, ElectraDx, SureSensors continuity, LKM).
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 1:52 AM
$LMDX $FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:55 AM
$FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:52 AM
$LMDX $RHHBY $FCN $SPY $ELECTRADX $TAUN Here’s more info, imo from a shareholder perspective, the sequence of events surrounding Invita, LumiraDx, and ElectraDx raises multiple red flags consistent with potential asset diversion, insider preference, and misleading financial disclosure. Invita Technologies was formally separated from LumiraDx in September 2023—immediately prior to the company’s abrupt collapse in reported assets, including a documented loss of approximately $50 million in total and current assets within a two-month period. During the same window, LumiraDx executives publicly claimed that digital assets and software platforms remained part of the group, yet Invita—housing precisely those assets—was quietly removed from the balance sheet. Shortly thereafter, key technical, scientific, and digital-infrastructure personnel who had built LumiraDx’s proprietary systems resurfaced at ElectraDx, an entity controlled by Ron Zwanziger and other former LumiraDx insiders.
1 · Reply
Iightning
Iightning Dec. 3 at 9:19 AM
1ightning® Premium Options Alert (Actionable) Ticker: $FCN Contract: Dec 19 $150C Entry: 16.50 Exit: 21.15 Return: +28.15% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 3:20 AM
$LMDX $RHHBY $SPY $FCN $ELECTRADX $TAUNS In my opinion, the timing of the Invita separation, the sudden deterioration of LumiraDx’s balance sheet, and the rapid emergence of ElectraDx with many of the same insiders is too aligned to ignore. Taken together, these events strongly suggest that key digital assets were repositioned ahead of insolvency, creating a continuity structure that benefited insiders while shareholders were wiped out.
0 · Reply
Iightning
Iightning Dec. 1 at 11:20 PM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $FCN **Contract:** Dec 19 $165C **Entry:** 4.57 **Exit:** 7.61 **Return:** **+66.27% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 29 at 3:08 PM
$LMDX $SPY $RHHBY $FCN Documented Events and Financial Outcomes in the LumiraDx Collapse 1. LumiraDx was once valued at $5 billion. 2. The Roche deal delivered only about $300 million. 3. Shareholders lost roughly $4.7 billion in value. 4. Ron Zwanziger and his affiliated family entities collectively owned approximately 25.5 percent of all LumiraDx common shares. 5. ElectraDx raised $14 million shortly after key LumiraDx resignations. Key R&D personnel and with POC tech. 6. Lumira Colombia was disposed of for near-zero value. 7. LumiraDx received multiple patents in mid and late 2024, after the company was already in dissolution. 8. The LumiraDx TB diagnostic patent was approved after the Roche transaction, meaning the technology was still active and valuable but never included in the sale valuation. 9. Invita Technologies was separated out prior to the Roche deal, removing assets from the group before the sale. 10. Shareholders ultimately recovered $0.
1 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 27 at 1:35 PM
$LMDX $RHHBY $FCN $ELECTRADX Hey there ☝️, it's time to talk turkey.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 27 at 3:15 AM
$LMDX $SPY $FCN 👁️👁️
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 27 at 3:15 AM
$FCN $LMDX $RHHBY $SPY 👁️👁️
0 · Reply
Iightning
Iightning Nov. 26 at 2:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $FCN Dec 19 $165 Call | Enter: $4.21 Exit: $6.31 | Profit: 49.68% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 12:14 PM
1ightning® Options Trade Alert (Actionable) | Buy $FCN Dec 19 $165 Call | Enter: $4.21 Exit: $6.31 | Profit: 49.68% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:10 AM
1ightning® Options Trade Alert (Actionable) | Buy $FCN Dec 19 $165 Call | Enter: $4.21 Exit: $6.31 | Profit: 49.68% ROI | https://1ightning.com
0 · Reply
Estimize
Estimize Nov. 24 at 1:03 PM
Wall St is expecting 1.46 EPS for $FCN Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/fcn?chart=historical&metric_name=eps&utm_cont
0 · Reply
Iightning
Iightning Nov. 21 at 10:27 PM
1ightning® Options Trade Alert (Actionable) | Buy $FCN Dec 19 $165 Call | Enter: $4.34 Exit: $5.42 | Profit: 24.91% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 21 at 5:45 PM
0 · Reply
Iightning
Iightning Nov. 21 at 1:41 AM
1ightning® Options Trade Alert (Actionable) | Buy $FCN Dec 19 $165 Call | Enter: $4.34 Exit: $5.42 | Profit: 24.91% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:05 PM
1ightning® Options Trade Alert (Actionable) | Buy $FCN Dec 19 $165 Call | Enter: $4.34 Exit: $5.42 | Profit: 24.91% ROI | https://1ightning.com
0 · Reply